IBDEI0C3 ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16116,0)
 ;;=203.00^^98^880^99
 ;;^UTILITY(U,$J,358.3,16116,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16116,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,16116,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,16116,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,16117,0)
 ;;=203.01^^98^880^98
 ;;^UTILITY(U,$J,358.3,16117,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16117,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,16117,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,16117,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,16118,0)
 ;;=238.6^^98^880^102
 ;;^UTILITY(U,$J,358.3,16118,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16118,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,16118,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,16118,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,16119,0)
 ;;=205.00^^98^880^5
 ;;^UTILITY(U,$J,358.3,16119,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16119,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,16119,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,16119,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,16120,0)
 ;;=205.01^^98^880^4
 ;;^UTILITY(U,$J,358.3,16120,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16120,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,16120,1,5,0)
 ;;=5^AML in Remission
 ;;^UTILITY(U,$J,358.3,16120,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,16121,0)
 ;;=205.10^^98^880^29
 ;;^UTILITY(U,$J,358.3,16121,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16121,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,16121,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,16121,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,16122,0)
 ;;=205.11^^98^880^28
 ;;^UTILITY(U,$J,358.3,16122,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16122,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,16122,1,5,0)
 ;;=5^CML in Remission
 ;;^UTILITY(U,$J,358.3,16122,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,16123,0)
 ;;=289.0^^98^880^52
 ;;^UTILITY(U,$J,358.3,16123,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16123,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,16123,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,16123,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,16124,0)
 ;;=238.4^^98^880^103
 ;;^UTILITY(U,$J,358.3,16124,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16124,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,16124,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,16124,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,16125,0)
 ;;=V58.61^^98^880^124
 ;;^UTILITY(U,$J,358.3,16125,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16125,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,16125,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,16125,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,16126,0)
 ;;=282.49^^98^880^116
 ;;^UTILITY(U,$J,358.3,16126,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16126,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,16126,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,16126,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,16127,0)
 ;;=289.89^^98^880^18
 ;;^UTILITY(U,$J,358.3,16127,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16127,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,16127,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,16127,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,16128,0)
 ;;=238.79^^98^880^85
 ;;^UTILITY(U,$J,358.3,16128,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16128,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,16128,1,5,0)
 ;;=5^Lymph/Hematpoietc Tis NEC
 ;;^UTILITY(U,$J,358.3,16128,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,16129,0)
 ;;=287.30^^98^880^104
 ;;^UTILITY(U,$J,358.3,16129,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16129,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,16129,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,16129,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,16130,0)
 ;;=288.09^^98^880^8
 ;;^UTILITY(U,$J,358.3,16130,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16130,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,16130,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,16130,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,16131,0)
 ;;=284.81^^98^880^15
 ;;^UTILITY(U,$J,358.3,16131,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16131,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,16131,1,5,0)
 ;;=5^Aplastic Due To Drugs
 ;;^UTILITY(U,$J,358.3,16131,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,16132,0)
 ;;=284.89^^98^880^14
 ;;^UTILITY(U,$J,358.3,16132,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16132,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,16132,1,5,0)
 ;;=5^Aplastic Anemia due to Chr disease
 ;;^UTILITY(U,$J,358.3,16132,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,16133,0)
 ;;=284.9^^98^880^12
 ;;^UTILITY(U,$J,358.3,16133,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16133,1,4,0)
 ;;=4^284.9
 ;;^UTILITY(U,$J,358.3,16133,1,5,0)
 ;;=5^Aplastic Anemia NOS
 ;;^UTILITY(U,$J,358.3,16133,2)
 ;;=^7020
 ;;^UTILITY(U,$J,358.3,16134,0)
 ;;=289.84^^98^880^117
 ;;^UTILITY(U,$J,358.3,16134,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16134,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,16134,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,16134,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,16135,0)
 ;;=204.02^^98^880^3
 ;;^UTILITY(U,$J,358.3,16135,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16135,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,16135,1,5,0)
 ;;=5^ALL, In Relapse
 ;;^UTILITY(U,$J,358.3,16135,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,16136,0)
 ;;=204.12^^98^880^25
 ;;^UTILITY(U,$J,358.3,16136,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16136,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,16136,1,5,0)
 ;;=5^CLL in Remission
 ;;^UTILITY(U,$J,358.3,16136,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,16137,0)
 ;;=204.21^^98^880^112
 ;;^UTILITY(U,$J,358.3,16137,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16137,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,16137,1,5,0)
 ;;=5^Subacute LL in Remission
 ;;^UTILITY(U,$J,358.3,16137,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,16138,0)
 ;;=204.20^^98^880^113
 ;;^UTILITY(U,$J,358.3,16138,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16138,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,16138,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,16138,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,16139,0)
 ;;=204.22^^98^880^114
 ;;^UTILITY(U,$J,358.3,16139,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16139,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,16139,1,5,0)
 ;;=5^Subacute LL, in Relapse
 ;;^UTILITY(U,$J,358.3,16139,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,16140,0)
 ;;=203.02^^98^880^100
 ;;^UTILITY(U,$J,358.3,16140,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16140,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,16140,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,16140,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,16141,0)
 ;;=205.02^^98^880^6
 ;;^UTILITY(U,$J,358.3,16141,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16141,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,16141,1,5,0)
 ;;=5^AML, In Relapse
 ;;^UTILITY(U,$J,358.3,16141,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,16142,0)
 ;;=205.12^^98^880^27
 ;;^UTILITY(U,$J,358.3,16142,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16142,1,4,0)
 ;;=4^205.12
 ;;^UTILITY(U,$J,358.3,16142,1,5,0)
 ;;=5^CML in Relapse
 ;;^UTILITY(U,$J,358.3,16142,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,16143,0)
 ;;=V10.91^^98^880^63
 ;;^UTILITY(U,$J,358.3,16143,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16143,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,16143,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,16143,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,16144,0)
 ;;=V10.91^^98^880^72
 ;;^UTILITY(U,$J,358.3,16144,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16144,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,16144,1,5,0)
 ;;=5^H/O Unspecified Malignant Neoplasm
 ;;^UTILITY(U,$J,358.3,16144,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,16145,0)
 ;;=465.9^^98^881^73
 ;;^UTILITY(U,$J,358.3,16145,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16145,1,4,0)
 ;;=4^465.9
 ;;^UTILITY(U,$J,358.3,16145,1,5,0)
 ;;=5^Uri
 ;;^UTILITY(U,$J,358.3,16145,2)
 ;;=URI^269878
 ;;^UTILITY(U,$J,358.3,16146,0)
 ;;=462.^^98^881^60
 ;;^UTILITY(U,$J,358.3,16146,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16146,1,4,0)
 ;;=4^462.
 ;;^UTILITY(U,$J,358.3,16146,1,5,0)
 ;;=5^Sore Throat
 ;;^UTILITY(U,$J,358.3,16146,2)
 ;;=^2653
 ;;^UTILITY(U,$J,358.3,16147,0)
 ;;=466.0^^98^881^3
 ;;^UTILITY(U,$J,358.3,16147,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16147,1,4,0)
 ;;=4^466.0
 ;;^UTILITY(U,$J,358.3,16147,1,5,0)
 ;;=5^Bronchitis,Acute
 ;;^UTILITY(U,$J,358.3,16147,2)
 ;;=^259084
 ;;^UTILITY(U,$J,358.3,16148,0)
 ;;=112.1^^98^881^78
 ;;^UTILITY(U,$J,358.3,16148,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16148,1,4,0)
 ;;=4^112.1
 ;;^UTILITY(U,$J,358.3,16148,1,5,0)
 ;;=5^Vulvovaginitis,Candidal
 ;;^UTILITY(U,$J,358.3,16148,2)
 ;;=^18615
 ;;^UTILITY(U,$J,358.3,16149,0)
 ;;=616.0^^98^881^13
 ;;^UTILITY(U,$J,358.3,16149,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16149,1,4,0)
 ;;=4^616.0
 ;;^UTILITY(U,$J,358.3,16149,1,5,0)
 ;;=5^Cervicitis
 ;;^UTILITY(U,$J,358.3,16149,2)
 ;;=^21925
 ;;^UTILITY(U,$J,358.3,16150,0)
 ;;=599.0^^98^881^74
 ;;^UTILITY(U,$J,358.3,16150,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16150,1,4,0)
 ;;=4^599.0
 ;;^UTILITY(U,$J,358.3,16150,1,5,0)
 ;;=5^UTI
 ;;^UTILITY(U,$J,358.3,16150,2)
 ;;=UTI^124436
 ;;^UTILITY(U,$J,358.3,16151,0)
 ;;=460.^^98^881^45
 ;;^UTILITY(U,$J,358.3,16151,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16151,1,4,0)
 ;;=4^460.
 ;;^UTILITY(U,$J,358.3,16151,1,5,0)
 ;;=5^Nasopharyngitis, Acute
 ;;^UTILITY(U,$J,358.3,16151,2)
 ;;=^26543
 ;;^UTILITY(U,$J,358.3,16152,0)
 ;;=372.30^^98^881^14
 ;;^UTILITY(U,$J,358.3,16152,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16152,1,4,0)
 ;;=4^372.30
 ;;^UTILITY(U,$J,358.3,16152,1,5,0)
 ;;=5^Conjunctivitis
 ;;^UTILITY(U,$J,358.3,16152,2)
 ;;=^27546
 ;;^UTILITY(U,$J,358.3,16153,0)
 ;;=595.9^^98^881^15
 ;;^UTILITY(U,$J,358.3,16153,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16153,1,4,0)
 ;;=4^595.9
